Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45

International Journal of Cancer

Volumn 121, Issue 1, 2007, Pages 193-198

  Chen, Zigui ^a   Fu, Leiping ^a   Herrero, Rolando ^b   Schiffman, Mark ^c   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Proyecto Epidemiologico Guanacaste   (Costa Rica)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Evolution; Human papillomavirus; Novel type; Phylogeny

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 97; IN VITRO STUDY; MOLECULAR CLONING; NORMAL HUMAN; OPEN READING FRAME; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; STEADY STATE; VIRUS IDENTIFICATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; CELL LINE; FEMALE; GENOME, VIRAL; HISPANIC AMERICANS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; OPEN READING FRAMES; PHYLOGENY; PREVALENCE; PROTEIN BINDING; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS;

EID: 34248550705     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22632     Document Type: Article

References (39)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
4. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
5. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):S42-S51.
6. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-14.
7. El Awady MK, Kaplan JB, O'Brien SJ, Burk RD. Molecular analysis of integrated human papillomavirus 16 sequences in the cervical cancer cell line SiHa. Virology 1987;159:389-98.
8. Soeda E, Ferran MC, Baker CC, McBride AA. Repression of HPV16 early region transcription by the E2 protein. Virology 2006;351:29-41.
9. Lindel K, Burri P, Studer HU, Altermatt HJ, Greiner RH, Gruber G. Human papillomavirus status in advanced cervical cancer: predictive and prognostic significance for curative radiation treatment. Int J Gynecol Cancer 2005;15:278-84.
10. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia. Mol Diagn 2004;8:57-64.
11. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
12. Castle PE, Schiffman M, Gravitt P, Kendall H, Fishman S, Hildesheim A, Herrero R, Bratti MC, Sherman M, Lorincz A, Schussler JE, Burk RD. Evaluation of HPV DNA detection by PCR. J Med Virol 2002;68:417-23.
13. Terai M, Burk RD. Complete nucleotide sequence and analysis of a novel human papillomavirus (HPV 84) genome cloned by an overlapping PCR method. Virology 2001;279:109-15.
14. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL
15. Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics 2001;17:754-5.
16. Swofford DL. PAUP, version 4. Phylogenetic Analysis Using Parsimony. Sunderland, MA: Sinauer, 1998.
17. Lu JZ, Sun YN, Rose RC, Bonnez W, McCance DJ. Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. J Virol 1993;67:7131-9.
18. Lee D, Kim H, Lee Y, Choe J. Identification of sequence requirement for the origin of DNA replication in human papillomavirus type 18. Virus Res 1997;52:97-108.
19. Chan WK, Chong T, Bernard HU, Klock G. Transcription of the transforming genes of the oncogenic human papillomavirus-16 is stimulated by tumor promoters through API binding sites. Nucleic Acids Res 1990;18:763-9.
20. Apt D, Chong T, Liu Y, Bernard HU. Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. J Virol 1993;67:4455-63.
21. Gloss B, Bernard HU. The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J Virol 1990;64:5577-84.
22. Ishiji T, Lace MJ, Parkkinen S, Anderson RD, Haugen TH, Cripe TP, Xiao JH, Davidson I, Chambon P, Turek LP. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J 1992;11:2271-81.
23. Dong XP, Stubenrauch F, Beyer-Finkler E, Pfister H. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int J Cancer 1994;58:803-8.
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
25. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
26. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90:3988-92.
27. Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986;154:665-72.
28. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, Schiller JT. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 1991; 65:4860-6.
29. Smotkin D, Prokoph H, Wettstein FO. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989;63:1441-7.
30. Wemess BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
31. Yasumoto S, Burkhardt AL, Doniger J, DiPaolo JA. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol 1986;57:572-7.
32. Matlashewski G, Schneider J, Banks L, Jones N, Murray A, Crawford L. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J 1987;6:1741-6.
33. Munger K, Phelps WC, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
34. Zhang B, Chen W, Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci USA 2006;103:437-42.
35. Demers GW, Foster SA, Halbert CL, Galloway DA. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 1994;91:4382-6.
36. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8:4099-105.
37. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity o the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 1992;89:4442-6.
38. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006;118:1071-6.
39. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003;95:1062-71.